Pubblicazioni

Autori:

Chiricozzi, Andrea; DAL BELLO, Giacomo; Gori, Niccolò; Di Nardo, Lucia; Schena, Donatella; Caldarola, Giacomo; Maurelli, Martina; De Simone, Clara; Girolomoni, Giampiero; Peris, Ketty

Titolo:

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Anno:

2023

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

The Journal of dermatological treatment.

ISSN Rivista:

1471-1753

Intervallo pagine:

1-6

Parole chiave:

Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal.

Breve descrizione dei contenuti:

Background: Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective: This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. Materials and methods: This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. Results: A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3–4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06–2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87–10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12–2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Conclusion: Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal.

Id prodotto:

134729

Handle IRIS:

11562/1099646

ultima modifica:

30 ottobre 2024

Citazione bibliografica:

Chiricozzi, Andrea; DAL BELLO, Giacomo; Gori, Niccolò; Di Nardo, Lucia; Schena, Donatella; Caldarola, Giacomo; Maurelli, Martina; De Simone, Clara; Girolomoni, Giampiero; Peris, Ketty, Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study « The Journal of dermatological treatment.» , 2023 , pp. 1-6

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo